CEACAM1 and CD105 expression in endometrial cancer and
|Course||Obstetrics and Gynaecology|
|Keywords||Endometrial cancer CEACAM1 CD105|
Objective: carcinoembryonic antigen-related cell adhesion molecule 1 (CEA-related cell adhesionmolecular1, CEACAM1) expression in endometrial cancer and significance, and CD105 (Endoglin) expression in endometrial carcinoma. Methods: Affiliated Hospital of Qingdao University Medical College and east Qingdao Municipal Hospital between January 1997 to June 2001 admitted patients with endometrial cancer surgical resection specimens of 52 cases, the average age of 56.6 (31-76) years of age. 22 cases of normal endometrium for the control group, obtained from the patients underwent surgical resection of uterine fibroids, the average age of 41 (35-56) years. All cases were pathologically confirmed. FIGO clinical staging and pathological grading standards. Using immunohistochemical methods to detect CEACAM1 and CD105 expression in normal endometrium and endometrial cancer, and to analyze the relationship of both expression and different clinicopathological parameters of the relationship between the two. Application of SPSS (13.0 FORWINDOWS) package for statistical analysis. Results in normal endometrium: 1.CEACAM1 expressed mainly in the top of the cell membrane, significantly reduced expression in endometrial cancer, and its expression site expressed throughout the cell membrane. CEACAM1 expression in normal endometrium higher than the expression in endometrial cancer, and the difference was statistically significant (P <0.05). 2.CEACAM1 expression in endometrial carcinoma: pathological grade three groups were compared using chi-square test, P = .4976; myometrial invasion among the three groups, P = 0.6927; CEACAM1 expression in endometrial cancer with age independent of the pathological grade and myometrial invasion, and surgical - pathologic stage and lymph node metastasis (P <0.05), and a negative correlation, that is, with the increase in the degree of malignancy of endometrial cancer, poor prognosis, CEACAM1 the expression decrease. 3.CD105 expression in normal endometrium and endometrial cancer: CD105 monoclonal antibody-positive cells in parts of the cytoplasm of the cell membrane and cytoplasm of endothelial cells, membrane coloring emphasis on. The dyeing results show that the expression of CD105 in endometrial cancer microvessel strong endometrial cancer tissue microvascular staining brownish yellow, showed a streak or sinus gap-like diffuse distribution, but weak staining in normal tissues. Statistical analysis, CD105 expression in endometrial cancer was significantly higher than that in normal endometrium, highly statistically significant difference (P <0.01). 4.CD105 expression in endometrial cancer: CD105 expression in endometrial cancer and age, pathological grade, and high pairwise comparison q test found three samples, poorly differentiated degree of group, P values ??greater than 0.05, the difference was not statistically significant; found in a packet of myometrial invasion, superficial muscle and deep myometrial both groups, P values ??less than 0.05, there are significant differences. CD105 and surgery - pathological stage and lymph node metastasis significant correlation (P <0.05), and lymph node metastasis was significantly higher than that without lymph node metastasis. Than normal endometrial 5.CEACAM1 expression in endometrial cancer express less, but not CEACAM1 in endometrial cancer expression in neovascular endothelial cells, but expression in the cell membrane through correlation analysis CEACAM1 and CD105 between no correlation (r = 0.015, P = 0.919). Conclusion: 1.CEACAM1 expressed in normal endometrium, endometrial carcinoma expression was significantly decreased, suggesting that CEACAM1 may suppress tumor development, is a tumor suppressor. Its expression site for expression in the entire endometrial cancer cell membrane, suggesting that CEACAM1 may play to maintain normal tissue structure and the role of cell polarity transition from the top of the membrane in the normal endometrium. 2.CEACAM1 expression in endometrial cancer in each group, age, tumor grade and myometrial infiltration has nothing to do with surgery - pathological stage and lymph node metastasis related (P <0.05), and showed a negative correlation. Again suggest that it may be a tumor suppressor, and decreased expression with increasing degree of malignancy, and therefore of CEACAM1 further research benefit the diagnosis and treatment of endometrial cancer gene. 3.CEACAM1 not obvious in the vascular expression in both normal endometrium or endometrial cancer, its antineoplastic effect may not be dependent on blood vessels, lymphatic depends on, this is the next step test to study the content. Review research literature abroad, fully illustrated that CEACAM1 might have different expression in different tissues, as to how to express it needs further study. Endometrial carcinoma with age 4.CD105 in histological grade, and found no significant differences in the pairwise comparison of the pathological grade; grouping of myometrial invasion found, superficial muscle and deep muscle layer in both groups there was significant difference, without myometrial invasion group found no differences between the two groups. CD105 and surgery - pathological stage and lymph node metastasis significant correlation (P <0.05), and lymph node metastasis was significantly higher than that without lymph node metastasis. Thus, CD105 marker intratumoral microvessel count (MVD) on the assessment of the degree of malignancy of endometrial cancer.